Adial Pharmaceuticals, Inc. Business Combination, Consideration Transferred
Adial Pharmaceuticals, Inc. (ADIL) reported Business Combination, Consideration Transferred of $41.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. business combination, consideration transferred for fiscal 2022 was $2.14M.
| Period end | Business Combination, Consideration Transferred 6 month | Business Combination, Consideration Transferred 12 month |
|---|---|---|
| 2026-06-30 | $41.50M 10-Q · filed 2026-08-14 | |
| 2022-12-31 | $2.14M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |